(AOF) – Euroapi has unveiled solid half-year results. The former subsidiary of Sanofi specializing in active ingredients and listed on the stock market last May achieved a net profit of 16.7 million euros over the first six months of the year, compared to a loss of 1.1 million a year. earlier. Core Ebitda reached 70.3 million, up 91.6%, showing a core Ebitda margin of 14.5%, an improvement of 128 basis points thanks to higher volumes and prices. Turnover increased by 10.1% to 483.8 million euros.
On the strength of these results, the group has confirmed its forecasts for consolidated revenue (around 1 billion euros) and “core” EBITDA margin (greater than or equal to 14%).
It raised its investment ratio forecast to around 14% of turnover (around 12% previously) in order to support the group’s growth in a context of high inflation.
In the current context, Euroapi remains confident in its ability to achieve its medium-term financial objectives.
AOF – LEARN MORE
An inevitable race for new blockbusters
The patent for Merck’s star product, the cancer drug Keytruda, which accounts for more than 35% of its sales, expires in 2028. Despite the loss, since 2019, of the patents for its three star products (Avastin, Herceptine, Rituxan) Roche was able to renew its portfolio by bringing new molecules to market. However, the discovery and launch of new drugs are increasingly expensive. AstraZeneca spends about $6 billion a year on R&D in a pharmaceutical industry where the life of a patent only lasts ten to fifteen years. This leads laboratories to withdraw from certain activities. Thus J&J, Pfizer, GSK and, no doubt, Novartis soon prefer to refocus on specialty drugs and abandon any ancillary activity.